Australia - engleză - Department of Health (Therapeutic Goods Administration)

pharmacare laboratories pty ltd - ascorbic acid, quantity: 80 mg; zinc sulfate monohydrate, quantity: 6.864 mg (equivalent: zinc, qty 2.5 mg) - pastille - excipient ingredients: carnauba wax; sucralose; maltitol solution; gelatin; vegetable oil; glycerol; purified water; colour; hypromellose; sorbitol; pectin; medium chain triglycerides; flavour - antioxidant/reduce free radicals formed in the body ; maintain/support healthy growth and development ; maintain/support general health and wellbeing ; maintain/support immune system health ; maintain/support healthy immune system function ; maintain/support immune system to fight illness ; aid/assist/helps protein synthesis in the body ; maintain/support (state vitamin/mineral/nutrient) levels in the body ; maintain/support skin health

Australia - engleză - Department of Health (Therapeutic Goods Administration)

pharmacare laboratories pty ltd - withania somnifera, quantity: 8.75 mg (equivalent: withania somnifera, qty 43.75 mg); matricaria chamomilla, quantity: 25 mg (equivalent: matricaria chamomilla, qty 200 mg) - pastille - excipient ingredients: purified water; silicon dioxide; steviol glycosides; maltodextrin; gelatin; glycerol; maltitol solution; carnauba wax; malic acid; vegetable oil; flavour; colour - antioxidant/reduce free radicals formed in the body ; maintain/support general health and wellbeing ; aids/assists the body to cope with environmental stress ; enhance/promote body adaptation to stress ; support healthy stress response in the body ; calms the mind ; help maintain/support emotional wellbeing ; aid/assist/helps mind relaxation ; decrease/reduce/relieve symptoms of stress (linked indication:maintains/supports refreshing sleep; decrease/reduce/relieve sleeplessness; decrease/reduce time to fall asleep; decrease/reduce/relieve disturbed/restless sleep; enhance/improve/promote/increase sleep quality/deep sleep); decrease/reduce/relieve nervous tension/unrest

Malaezia - engleză - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

kin bio sdn. bhd. - maca (lepidium meyenii) -

Regatul Unit - engleză - MHRA (Medicines & Healthcare Products Regulatory Agency)

inmunotek - macadamia allergen extract - solution for skin-prick test

Uniunea Europeană - engleză - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - cystic fibrosis - other respiratory system products - orkambi tablets are indicated for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who are homozygous for the f508del mutation in the cftr gene.orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Malta - engleză - Medicines Authority

pharmacare srl - dutasteride - soft capsule - dutasteride 0.5 mg - urologicals

Israel - engleză - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 100 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who are homozygous for the f508del mutation in the cftr gene limitations of use the efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation

Israel - engleză - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 100 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who are homozygous for the f508del mutation in the cftr gene limitations of use the efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation

Israel - engleză - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 12 years and older who are homozygous for the f508del mutation in the cftr gene.if the patient's genotype is unknown, cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene.limitations of usethe efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation.

Israel - engleză - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 12 years and older who are homozygous for the f508del mutation in the cftr gene.if the patient's genotype is unknown, cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene.limitations of usethe efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation.